|
Strand Life Sciences a leading genomics and bioinformatics firm launched a blood-based test for early detection of multiple cancers. CancerSpot uses latest globally accepted methylation profiling technology to identify cancer tumour DNA fragments.
The test works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood, Strand Life Sciences, a subsidiary of Reliance Industries, said in a statement.
"Cancer in India is emerging as a major cause of morbidity and mortality. It is a source of heavy financial, social and psychological burden on patients, families and communities," stated Isha Ambani Piramal, Reliance Industries Member of the Board.
"Therefore, Strand's novel cancer early detection test exemplifies our vision of delivering transformative healthcare solutions,” she added.
The company is committed to utilising the power of genomics in advancing healthcare and wellness, and improving lives in India, as well as the rest of the world. "Over our 24-year history, Strand has been a pioneer in genomics, and this is another first for India resulting from a rigorous multi-year research study," Ramesh Hariharan, CEO and co-founder, Strand Life Sciences.
|